As I am one who always stresses that we need to continually read and learn about our disease, especially since anything with the lungs are vitally important to our survival.
Hence, the following is a write I found on sciencedaily.com from some research done at Monash University in Australia.
While some, if not much may be above my head in terminology – I found it of interest as I not only have late State III COPD, but also severe Asthma – a very frustrating combination at times.
This article was published in June of 2017.
‘Unique Stem Cells as a Potential Asthma Treatment’
A new therapy developed through stem cell technology holds promise as a treatment for chronic asthma.
A study led by scientists at Monash University has shown that a new therapy developed through stem cell technology holds promise as a treatment for chronic asthma.
The Monash Biomedicine Discovery Institute (BDI) scientists provided the experimental expertise to test Cynata Therapeutics’ induced pluripotent stem cell-derived mesenchymal stem cells (MSCs) in a model of experimental asthma. Induced pluripotent stem cells are a type of pluripotent stem cell that can be generated directly from adult cells; they have the ability to be differentiated into a variety of tissue types and, in this case, MSCs that can regenerate damaged lung tissue.
Lead researchers Associate Professor Chrishan Samuel and Dr. Simon Royce tested the efficacy of the MSCs on three key components of asthma in a preclinical model of chronic allergic airways disease: inflammation; airway remodeling (structural changes that occur in lungs as a result of prolonged inflammation); and airway hyperresponsiveness (the clinical symptom of asthma).
The study, published in the FASEB Journal, found that the MSCs could effectively reduce inflammation, reversed signs of airway remodeling and completely normalized airway/lung fibrosis and airway hyperresponsiveness, particularly when delivered intranasally.
It concluded that they may provide a novel stand-along therapy or an adjunct therapy for groups of asthma sufferers who do not respond to current (corticosteroid) therapy.
“Most importantly, what we found was you can treat fibrosis (hardening or scarring of the lung) very effectively,” said Associate Professor Samuel, who heads the Monash BDI’s Fibrosis Laboratory.
“When we’ve tested other types of stem cells they haven’t been able to fully reverse scarring and lung dysfunction associated with asthma – we’ve had to combine them with anti-scarring drugs to achieve that. These cells were remarkable on their own as they were able to effectively reverse the scarring that contributes to lung dysfunction and difficulty in breathing,” he said.
One in nine – or around 2.5 million – Australians have asthma.
Further research will be conducted to test the MSCs in combination with or compared to a clinically-used corticosteroid. Clinical trials using the cells as a novel target for asthma are then envisaged.
Cynata Therapeutics Limited is an Australian clinical-stage stem cell and regenerative medicine company developing therapies based on its proprietary Cymerus™ stem cell technology platform.
Read the full paper titled intranasal administration of mesenchymoangioblast-derived mesenchymal stem cells abrogates airway fibrosis and airway hyperresponsiveness associated with chronic allergic airways disease published in the FASEB Journal.
Source of the Story:
Materials provided by Monash University. Note: Content was edited for style and length.
Simon G. Royce, Siddharth Rele, Brad R. S. Broughton, Kilian Kelly, Chrishan S. Samuel. Intranasal administration of mesenchymoangioblast-derived mesenchymal stem cell abrogates airway fibrosis and airway hyperresponsiveness associated with chronic allergic airways disease. The FASEB Journal, 201y7; fj.201700178R DOI: 10.1096/fj.201700178R.